{"id":876,"date":"2022-05-27T00:00:00","date_gmt":"2022-05-27T00:00:00","guid":{"rendered":"https:\/\/www.lunit.io\/media-hub\/new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment\/"},"modified":"2022-05-27T00:00:00","modified_gmt":"2022-05-27T00:00:00","slug":"new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment","status":"publish","type":"media-hub","link":"https:\/\/www.lunit.io\/en\/media-hub\/new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment\/","title":{"rendered":"New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment"},"content":{"rendered":"<ul>\n<li>\n<p>Lunit to showcase 7 poster presentations and 4 online publications, the company\u2019s largest publication set at ASCO to date<\/p>\n<\/li>\n<li>\n<p>Findings demonstrate the practical effectiveness of Lunit\u2019s AI solutions in the pathological assessment of tumors across more than 16 primary cancer types<\/p>\n<\/li>\n<\/ul>\n<p><\/p>\n<p><\/p>\n<p><strong><\/strong><\/p>\n<p><strong>[SEOUL, South Korea, May 27, 2022]<\/strong> New findings demonstrate the clinical efficacy of AI-powered tissue analysis as a guide in cancer treatment, according to medical AI provider Lunit. The findings will be presented at the 2022 ASCO Annual Meeting, to be held from June 3 to 7. This year\u2019s ASCO meeting will showcase the largest number of studies by Lunit, including seven poster presentations and four online publications.<\/p>\n<p>One of the poster presentations by Lunit elaborates on the validation of the Inflamed Immune Phenotype (IIP) as a practical biomarker to guide immune checkpoint inhibitor (ICI) treatment. The IIP is assessed by Lunit SCOPE IO, Lunit\u2019s AI-powered immune phenotype analyzer, from H&amp;E slide images.<\/p>\n<p>Lunit SCOPE IO analyzes a patient\u2019s cancer tissue slide image by observing the distribution of tumor-infiltrating lymphocytes \u2013 TILs \u2014 one of the immunocytes that fight cancer cells. Based on the spatial distribution pattern of TILs and cancer cells in the tumor microenvironment, Lunit SCOPE IO identifies the tissue sample as one of three immune phenotypes: inflamed, immune-excluded, or immune-desert.<\/p>\n<p><\/p>\n<p><\/p><figcaption>\n<p><img decoding=\"async\" src=\"\/en\/wp-content\/uploads\/EDITOR\/e1862c97-3438-4191-9f8e-03db5b9f7245.png#1300\">Lunit SCOPE IO \u25b2<\/p>\n<\/figcaption><p>Findings upon evaluation showed that the Inflamed Immune Phenotype (IIP) may represent a practical, clinically actionable biomarker predictive of favorable ICI treatment outcomes across more than 16 primary cancer types. This study included more than 1,800 samples paired with real-world clinical outcomes data.<\/p>\n<p>\u201cPatient outcomes after ICI treatment were analyzed with specific indicators including objective response rate and progression-free survival. This study is especially noteworthy in that it demonstrates the utility of the AI-assessed IIP as a biomarker across diverse cancer patient populations, including those with PD-L1 negative, MSS\/TMB-low tumors, in whom predictive biomarkers are urgently needed,\u201d said Chan-Young Ock, Chief Medical Officer at Lunit.<\/p>\n<p>Lunit will also deliver a presentation on Lunit SCOPE PD-L1 TPS, the company\u2019s AI-powered PD-L1 tumor proportion score (TPS) analyzer.<\/p>\n<p>\u201cWhile PD-L1 expression is the standard biomarker for advanced non-small cell lung cancer (NSCLC), manual evaluation of PD-L1 TPS by pathologists has practical limitations including interobserver variation and lengthy time demands,\u201d said Kyunghyun Paeng, Chief Product Officer of Lunit. \u201cThrough a randomized trial, this study aimed to test the benefit of our AI-based PD-L1 TPS analyzer in assisting pathologists\u2019 evaluation in terms of accuracy and evaluation time.\u201d<\/p>\n<p><\/p>\n<p><\/p><figcaption>\n<p><img decoding=\"async\" src=\"\/en\/wp-content\/uploads\/EDITOR\/d98cd90e-6837-43d8-8ca7-5351cc203c72.png#1302\">Lunit SCOPE PD-L1 \u25b2<\/p>\n<\/figcaption><p><\/p>\n<p><\/p>\n<p>12 board-certified pathologists scored the PD-L1 TPS of 199 NSCLC whole-slide images in two separate intervals, with and without AI assistance, respectively. The results demonstrated the feasibility of Lunit SCOPE PD-L1 TPS to assist pathologists\u2019 evaluation: with AI assistance, the overall accuracy of pathologists\u2019 TPS scores increased from 79.9% to 83.2%, while the mean reading time was reduced by 30%.<\/p>\n<p>Lunit SCOPE PD-L1 TPS recently received the CE mark, becoming the first Lunit SCOPE product to receive regulatory approval. Lunit is currently conducting a multi-center pivotal clinical trial in the U.S., following the results of this study.<\/p>\n<p>The company\u2019s other scheduled poster presentations include a clinical trial demonstrating the accuracy of Lunit\u2019s AI imaging solution in detecting high-risk breast cancer patients, as well as a study assessing the clinical efficacy of Lunit SCOPE IO in the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients.<\/p>\n<p>\u201cLunit has been presenting groundbreaking findings at ASCO every year since 2019, and we are proud to showcase our largest set of research yet with 11 abstracts,\u201d said Brandon Suh, CEO of Lunit. \u201cAs our AI biomarker platform continues to gain validation and recognition, we are expanding our early research and commercial access programs for Lunit SCOPE throughout the year.\u201d<\/p>\n<p><\/p>\n<p><\/p>\n<p><small><\/p>\n<p><strong>&lt;ASCO 2022\ub8e8\ub2db \ub2e8\ub3c5 \ubc0f \ud611\uc5c5 \uc5f0\uad6c\ucd08\ub85d \uc815\ubcf4&gt;<\/strong><\/p>\n<p><\/p>\n<ol>\n<li>\n<p><strong>#2621 . <\/strong><a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/209823\" target=\"_blank\">The inflamed immune phenotype (IIP): A clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across &gt;16 primary tumor types.<\/a> (Poster)<\/p>\n<\/li>\n<li>\n<p><strong>#8529. <\/strong><a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/209255\" target=\"_blank\">Observer performance study to examine the feasibility of the AI-powered PD-L1 analyzer to assist pathologists\u2019 assessment of PD-L1 expression using tumor proportion score in non\u2013small cell lung cancer.<\/a> (Poster)<\/p>\n<\/li>\n<li>\n<p><strong>#595.<\/strong> <a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/211008\" target=\"_blank\">Artificial intelligence (AI)\u2013powered spatial analysis of tumor-infiltrating lymphocytes (TIL) for prediction of response to neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC).<\/a> (Poster)<\/p>\n<\/li>\n<li>\n<p><strong>#2570. <\/strong><a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/209918\" target=\"_blank\">Artificial intelligence-powered pathology image analysis merged with spatial transcriptomics reveals distinct TIGIT expression in the immune-excluded tumor-infiltrating lymphocytes.<\/a> (Poster)<\/p>\n<\/li>\n<li>\n<p><strong>#4096. <\/strong><a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/210848\" target=\"_blank\">Trastuzumab plus FOLFOX for gemcitabine\/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14).<\/a> (Poster)<\/p>\n<\/li>\n<li>\n<p><strong>#10533.<\/strong> <a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/209807\" target=\"_blank\">Robust artificial intelligence-powered imaging biomarker based on mammography for risk prediction of breast cancer.<\/a> (Poster)<\/p>\n<\/li>\n<li>\n<p><strong>#2663. <\/strong><a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/210395\" target=\"_blank\">Tumor-infiltrating lymphocyte enrichment predicted by CT radiomic analysis is associated with clinical outcomes of immune checkpoint inhibitor in non\u2013small cell lung cancer.<\/a> (Poster)<\/p>\n<\/li>\n<li>\n<p><strong>#e12543. <\/strong><a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/212306\" target=\"_blank\">Artificial intelligence-powered human epidermal growth factor receptor 2 (HER2) analyzer in breast cancer as an assistance tool for pathologists to reduce interobserver variation.<\/a> (Online Publication Only)<\/p>\n<\/li>\n<li>\n<p><strong>#e16214. <\/strong> <a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/212211\" target=\"_blank\">Artificial intelligence-powered whole-slide image analyzer reveals a distinctive distribution of tumor-infiltrating lymphocytes in neuroendocrine tumors and carcinomas.<\/a> (Online Publication Only)<\/p>\n<\/li>\n<li>\n<p><strong>#e14557. <\/strong><a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/212664\" target=\"_blank\">Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors:A phase I study.<\/a> (Online Publication Only)<\/p>\n<\/li>\n<li>\n<p><strong>#e24001<\/strong>.  <a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/210497\" target=\"_blank\">Need of pretreatment support of breast cancer patient caregivers compared to patients.<\/a> (Online Publication Only)<\/p>\n<\/li>\n<\/ol>\n<p><\/p>\n<p><\/small><\/p>\n<p><\/p>\n<p><\/p>\n<p><\/p>\n<p><\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"template":"","media-hub-type":[35],"class_list":["post-876","media-hub","type-media-hub","status-publish","hentry","media-hub-type-precision-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment - Lunit<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lunit.io\/en\/media-hub\/new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment - Lunit\" \/>\n<meta property=\"og:description\" content=\"Lunit to showcase 7 poster presentations and 4 online publications, the company\u2019s largest publication set at ASCO to date Findings demonstrate the practical effectiveness of Lunit\u2019s AI solutions in the pathological assessment of tumors across more than 16 primary cancer types [SEOUL, South Korea, May 27, 2022] New findings demonstrate the clinical efficacy of AI-powered [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lunit.io\/en\/media-hub\/new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Lunit\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@lunit_ai\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/media-hub\\\/new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment\\\/\",\"url\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/media-hub\\\/new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment\\\/\",\"name\":\"New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment - Lunit\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/#website\"},\"datePublished\":\"2022-05-27T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/media-hub\\\/new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.lunit.io\\\/en\\\/media-hub\\\/new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/media-hub\\\/new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/#website\",\"url\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/\",\"name\":\"Lunit\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/#organization\",\"name\":\"Lunit\",\"url\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Logo-black.svg\",\"contentUrl\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Logo-black.svg\",\"width\":189,\"height\":52,\"caption\":\"Lunit\"},\"image\":{\"@id\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/lunit_ai\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/lunit-inc\",\"https:\\\/\\\/x.com\\\/lunitoncology\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment - Lunit","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lunit.io\/en\/media-hub\/new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment\/","og_locale":"en_US","og_type":"article","og_title":"New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment - Lunit","og_description":"Lunit to showcase 7 poster presentations and 4 online publications, the company\u2019s largest publication set at ASCO to date Findings demonstrate the practical effectiveness of Lunit\u2019s AI solutions in the pathological assessment of tumors across more than 16 primary cancer types [SEOUL, South Korea, May 27, 2022] New findings demonstrate the clinical efficacy of AI-powered [&hellip;]","og_url":"https:\/\/www.lunit.io\/en\/media-hub\/new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment\/","og_site_name":"Lunit","twitter_card":"summary_large_image","twitter_site":"@lunit_ai","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.lunit.io\/en\/media-hub\/new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment\/","url":"https:\/\/www.lunit.io\/en\/media-hub\/new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment\/","name":"New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment - Lunit","isPartOf":{"@id":"https:\/\/www.lunit.io\/ko\/#website"},"datePublished":"2022-05-27T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.lunit.io\/en\/media-hub\/new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lunit.io\/en\/media-hub\/new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.lunit.io\/en\/media-hub\/new-studies-at-asco-2022-validate-effectiveness-of-lunit-ai-as-diagnostic-aid-in-cancer-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lunit.io\/en\/"},{"@type":"ListItem","position":2,"name":"New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment"}]},{"@type":"WebSite","@id":"https:\/\/www.lunit.io\/ko\/#website","url":"https:\/\/www.lunit.io\/ko\/","name":"Lunit","description":"","publisher":{"@id":"https:\/\/www.lunit.io\/ko\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lunit.io\/ko\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.lunit.io\/ko\/#organization","name":"Lunit","url":"https:\/\/www.lunit.io\/ko\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.lunit.io\/ko\/#\/schema\/logo\/image\/","url":"https:\/\/www.lunit.io\/en\/wp-content\/uploads\/2025\/10\/Logo-black.svg","contentUrl":"https:\/\/www.lunit.io\/en\/wp-content\/uploads\/2025\/10\/Logo-black.svg","width":189,"height":52,"caption":"Lunit"},"image":{"@id":"https:\/\/www.lunit.io\/ko\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/lunit_ai","https:\/\/www.linkedin.com\/company\/lunit-inc","https:\/\/x.com\/lunitoncology"]}]}},"_links":{"self":[{"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/media-hub\/876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/media-hub"}],"about":[{"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/types\/media-hub"}],"author":[{"embeddable":true,"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/users\/3"}],"wp:attachment":[{"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/media?parent=876"}],"wp:term":[{"taxonomy":"media-hub-type","embeddable":true,"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/media-hub-type?post=876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}